181 related articles for article (PubMed ID: 37090101)
1. Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
Meyers DE; Pasternak M; Dolter S; Grosjean HAI; Lim CA; Stukalin I; Goutam S; Navani V; Heng DYC; Cheung WY; Morris DG; Pabani A
JTO Clin Res Rep; 2023 Apr; 4(4):100482. PubMed ID: 37090101
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
3. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
[TBL] [Abstract][Full Text] [Related]
4. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
5. First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.
Facchinetti F; Di Maio M; Perrone F; Tiseo M
Transl Lung Cancer Res; 2021 Jun; 10(6):2917-2936. PubMed ID: 34295688
[TBL] [Abstract][Full Text] [Related]
6. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.
Krishnan M; Kasinath P; High R; Yu F; Teply BA
JCO Oncol Pract; 2022 Jan; 18(1):e175-e182. PubMed ID: 34351819
[TBL] [Abstract][Full Text] [Related]
7. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
Gridelli C; Peters S; Mok T; Forde PM; Reck M; Attili I; de Marinis F
ESMO Open; 2022 Feb; 7(1):100355. PubMed ID: 34922299
[TBL] [Abstract][Full Text] [Related]
8. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
Kano H; Ichihara E; Harada D; Inoue K; Kayatani H; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Ninomiya K; Hotta K; Maeda Y; Kiura K
Cancer Sci; 2020 Oct; 111(10):3739-3746. PubMed ID: 32726470
[TBL] [Abstract][Full Text] [Related]
9. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Bilen MA; Santos V; Esther J; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Assi H; Gartrell BA; Sankin A; Rodriguez-Vida A; Lythgoe M; Pinato DJ; Drakaki A; Joshi M; Isaacsson Velho P; Hahn N; Liu S; Alonso Buznego L; Duran I; Moses M; Jain J; Murgic J; Baratam P; Barata P; Tripathi A; Zakharia Y; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Cancer; 2020 Mar; 126(6):1208-1216. PubMed ID: 31829450
[TBL] [Abstract][Full Text] [Related]
10. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
[TBL] [Abstract][Full Text] [Related]
11. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.
Mouritzen MT; Junker KF; Carus A; Ladekarl M; Meldgaard P; Nielsen AWM; Livbjerg A; Larsen JW; Skuladottir H; Kristiansen C; Wedervang K; Schytte T; Hansen KH; Østby AC; Frank MS; Lauritsen J; Sørensen JB; Langer SW; Persson GF; Andersen JL; Homann PH; Kristensen EB; Drivsholm LB; Bøgsted M; Christensen HS; Pøhl M; Bjørnhart B
Acta Oncol; 2022 Apr; 61(4):409-416. PubMed ID: 35012430
[TBL] [Abstract][Full Text] [Related]
12. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.
Shah NJ; Della Pia A; Wu T; Williams A; Weber M; Sinclaire B; Gourna Paleoudis E; Alaoui A; Lev-Ari S; Adams S; Kaufman J; Parikh SB; Tonti E; Muller E; Serzan M; Cheruku D; Lee A; Sridhar A; Hee BTP; Ahn J; Pecora A; Ip A; Atkins MB
Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927928
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review.
Mojsak D; Kuklińska B; Minarowski Ł; Mróz RM
Adv Med Sci; 2021 Sep; 66(2):381-387. PubMed ID: 34315013
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
Diker O; Olgun P; Balyemez U; Sigit Ikiz S
Cureus; 2023 Jan; 15(1):e33234. PubMed ID: 36733552
[TBL] [Abstract][Full Text] [Related]
18. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
Murakami Y; Tamiya A; Taniguchi Y; Adachi Y; Enomoto T; Azuma K; Inagaki Y; Kouno S; Matsuda Y; Okishio K; Atagi S
Thorac Cancer; 2022 Feb; 13(4):593-601. PubMed ID: 34989133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
